Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Herpes Simplex Virus Encephalitis Age: Adult |
Dose: Intravenous – 10-15 mg/kg Frequency: every 8 hours Duration: for 10 days; up to 14-21 days reported Note: Consideration should be given to dosage reduction in obese patients and especially in those with renal impairment or the elderly. In obese patients, higher plasma concentrations may be obtained when dosed based on actual body weight. |
|
Indication: Mucocutaneous Herpes Simplex Virus Infection Age: Adult Condition: immunocompromised patients |
Dose: Intravenous – 5 mg/kg Frequency: every 8 hours Duration: for 7 days; dosing up to 14 days reported Note: Consideration should be given to dosage reduction in obese patients and especially in those with renal impairment or the elderly. In obese patients, higher plasma concentrations may be obtained when dosed based on actual body weight. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Neonatal Herpes Simplex Virus Infection Age: Neonates and Infants up to 3 months Condition: Disseminated and Central Nervous System disease, Post Menstrual Age greater than 34 weeks |
Dose: Intravenous – 20 mg/kg Frequency: every 8 hours Duration: 21 days Note: calculated on the basis of body weight |
|
Indication: Neonatal Herpes Simplex Virus Infection Age: Neonates and Infants up to 3 months Condition: Disease limited to the skin and mucous membranes, Post Menstrual Age greater than 34 weeks |
Dose: Intravenous – 20 mg/kg Frequency: every 8 hours Duration: 14 days Note: calculated on the basis of body weight |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Renal impairment |
Dose: Intravenous – Recommended dose Frequency: every 12 hours Note: Renal impairment (intravenous) |
|
Age: Adult Condition: Renal impairment |
Dose: Intravenous – Recommended dose Frequency: every 24 hours Note: Renal impairment (intravenous) |
Administration
- Must be administered by healthcare professional
- Infuse over 1 hour
Side Effect
- Inflammation or phlebitis at injection site (9%)
- Nausea (7%)
- Vomiting (7%)
- Rash or hives (2%)
- Elevated transaminase levels (1-2%)
- pain
- Aggression/confusion
- Agitation
- Alopecia
- Anaphylaxis
- Anemia
- Angioedema
- Anorexia
- Ataxia
- Coma
- Disseminated intravascular coagulation (DIC)
- Dizziness
- Fatigue
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Probenecid, cimetidine, mycophenolate mofetil
|
May increase the plasma concentration of aciclovir
|
|
Drugs that affect renal physiology (e.g. ciclosporin, tacrolimus)
|
Increased nephrotoxic effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 15°C to 25°C. Protected from light and moisture. Keep the medicine out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.